A comparative study of the effects of genistein, estradiol and raloxifene on the murine skeletal system

Acta Biochimica Polonica

Volumn 56, Issue 2, 2009, Pages 261-270

  Śliwiński, Leszek ^a   Folwarczna, Joanna ^a   Nowińska, Barbara ^a   Cegieła, Urszula ^a   Pytlik, Maria ^a   Kaczmarczyk Sedlak, Ilona ^a   Trzeciak, Hanna ^a   Trzeciak, Henryk I ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Bone mechanical properties; Bone mineralization; Estradiol; Genistein; Osteoblasts; Osteoclasts; Raloxifene

Indexed keywords

MURINAE; RATTUS; RATTUS NORVEGICUS;

EID: 68249120572     PISSN: 0001527X     EISSN: 1734154X     Source Type: Journal    
DOI: 10.18388/abp.2009_2458     Document Type: Article

References (48)

1. Amano H, Yamada S, Felix R (1998) Colony-stimulating factor-1 stimulates the fusion process in osteoclasts. J Bone Miner Res 13: 846-853.
2. Baker VL, Leitman D, Jaffe RB (2000) Selective estrogen re-ceptor modulators in reproductive medicine and biology. Obstet Gynecol Surv 55 (Suppl 2): S21-S47.
3. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson JA, Nilsson S (1998) Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol Pharmacol 54: 105-112.
4. Blair HC, Jordan SE, Peterson TG, Barnes S (1996) Variable effects of tyrosine kinase inhibitors on avian osteo-clastic activity and reduction of bone loss in ovariecto-mized rats. J Cell Biochem 61: 629-637.
5. Cassidy A, Albertazzi P, Lise-Nielsen I, Hall W, Williamson G, Tetens I, Atkins S, Cross H, Manios Y, Wolk A, Steiner C, Branca F (2006) Critical review of health effects of soyabean phyto-oestrogens in post-menopausal women. Proc Nutr Soc 65: 76-92.
6. Chen XW, Garner SC, Anderson JJ (2002) Isoflavones regulate interleukin-6 and osteoprotegerin synthesis during osteoblast cell differentiation via an estrogen-receptor-dependent pathway. Biochem Biophys Res Commun 295: 417-422.
7. Deroo BJ, Korach KS (2006) Estrogen receptors and human disease. J Clin Invest 116: 561-570.
8. Erlandsson MC, Islander U, Moverare S, Ohlsson C, Carlsten H (2005) Estrogenic agonism and antagonism of the soy isoflavone genistein in uterus, bone and lymphopoiesis in mice. APMIS 113: 317-323.
9. Evans GL, Bryant HU, Magee DE, Turner RT (1996) Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia. Endocrinology 137: 4139-4144.
10. Farahbakhsh NA (2003) Ectonucleotidases of the rabbit ciliary body nonpigmented epithelium. Invest Ophthalmol Vis Sci 44: 3952-3960.
11. Folwarczna J, Janiec W, Śliwiński L (2004) Effects of heparin and low-molecular-weight heparins on bone mechanical properties in rats. Thromb Haemost 92: 940-946.
12. Gallo D, Zannoni GF, Apollonio P, Martinelli E, Ferlini C, Passetti G, Riva A, Morazzoni P, Bombardelli E, Scambia G (2005) Characterization of the pharmacologic profile of a standardized soy extract in the ovariectomized rat model of menopause: effects on bone, uterus, and lipid profile. Menopause 12: 589-600.
13. Gao YH, Yamaguchi M (1999) Inhibitory effect of genistein on osteoclast-like cell formation in mouse marrow cultures. Biochem Pharmacol 58: 767-772.
14. Gao YH, Yamaguchi M (2000) Suppressive effect of genistein on rat bone osteoclasts: involvement of protein kinase inhibition and protein tyrosine phosphatase activation. Int J Mol Med 5: 261-267.
15. García Palacios V, Robinson LJ, Borysenko CW, Lehmann T, Kalla SE, Blair HC (2005) Negative regulation of RANKL-induced osteoclastic differentiation in RAW264.7 cells by estrogen and phytoestrogens. J Biol Chem 280: 13720-13727.
16. Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millán JL (2004) Concerted regulation of inorganic pyrophosphate and osteopontin by Akp2, Enpp1, and Ank: an integrated model of the pathogenesis of miner-alization disorders. Am J Pathol 164: 1199-1209.
17. Hessle L, Johnson KA, Anderson HC, Narisawa S, Sali A, Goding JW, Terkeltaub R, Millán JL (2002) Tissue-non-specific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci USA 99: 9445-9449.
18. Hofbauer LC, Kühne CA, Viereck V (2004) The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 4: 268-275.
19. Kajiya H, Okabe K, Okamoto F, Tsuzuki T, Soeda H (2000) Protein tyrosine kinase inhibitors increase cytosolic calcium and inhibit actin organization as resorbing activity in rat osteoclasts. J Cell Physiol 183: 83-90.
20. Kalu DN (1991) The ovariectomized rat model of postmen-opausal bone loss. Bone Miner 15: 175-191.
21. Kryśkiewicz E, Lorenc RS (2006) RANKL/RANK/OPG system and its importance in bone physiology and pathophysiology. Terapia 3: 58-63.
22. Li X, Udagawa N, Itoh K, Suda K, Murase Y, Nishihara T, Suda T, Takahashi N (2002) p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 143: 3105-3113.
23. Liu BY, Guo J, Lanske B, Divieti P, Kronenberg HM, Bringhurst FR (1998) Conditionally immortalized murine bone marrow stromal cells mediate parathyroid hormone-dependent osteoclastogenesis in vitro. Endocrinology 139: 1952-1964.
24. Luben RA, Cohn DV (1976) Effects of parathormone and calcitonin on citrate and hyaluronate metabolism in cultured bone. Endocrinology 98: 413-419.
25. Ma DF, Qin LQ, Wang PY, Katoh R (2008) Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials. Eur J Clin Nutr 62: 155-161.
26. Mathey J, Mardon J, Fokialakis N, Puel C, Kati-Coulibaly S, Mitakou S, Bennetau-Pelissero C, Lamothe V, Davicco MJ, Lebecque P, Horcajada MN, Coxam V (2007) Modulation of soy isoflavones bioavailability and subsequent effects on bone health in ovariectomized rats: the case for equol. Osteoporos Int 18: 671-679.
27. McCarty MF (2006) Isoflavones made simple - genistein's agonist activity for the beta-type estrogen receptor mediates their health benefits. Med Hypotheses 66: 1093-1114.
28. McClain RM, Wolz E, Davidovich A, Pfannkuch F, Edwards JA, Bausch J (2006) Acute, subchronic and chronic safety studies with genistein in rats. Food Chem Toxicol 44: 56-80.
29. Migliaccio S, Anderson JJ (2003) Isoflavones and skeletal health: are these molecules ready for clinical application? Osteoporos Int 14: 361-368
30. Morris C, Thorpe J, Ambrosio L, Santin M (2006) The soybean isoflavone genistein induces differentiation of MG63 human osteosarcoma osteoblasts. J Nutr 136: 1166-1170.
31. Okumura N, Yoshikawa T, Iida J, Nonomura A, Takakura Y (2006) Bone formation-promoting effect of genistein on marrow mesenchymal cell culture. Biomed Mater Eng 16: 23-32.
32. Om A-S, Shim J-Y (2007) Effect of daidzein, a soy isoflavone, on bone metabolism in Cd-treated ovariectomized rats. Acta Biochim Polon 54: 641-646.
33. Pan W, Quarles LD, Song LH, Yu YH, Jiao C, Tang HB, Jiang CH, Deng HW, Li YJ, Zhou HH, Xiao ZS (2005) Genistein stimulates the osteoblastic differentiation via NO/cGMP in bone marrow culture. J Cell Biochem 94: 307-316.
34. Polkowski K, Mazurek AP (2000) Biological properties of genistein. A review of in vitro and in vivo data. Acta Pol Pharm 57: 135-155.
35. Pytlik M, Folwarczna J, Janiec W (2004) Effects of doxy-cycline on mechanical properties of bones in rats with ovariectomy-induced osteopenia. Calcif Tissue Int 75: 225-230.
36. Reinwald S, Weaver CM (2006) Soy isoflavones and bone health: a double-edged sword? J Nat Prod 69: 450-459
37. Raisz LG (2005) Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115: 3318-3325.
38. Rickard DJ, Monroe DG, Ruesink TJ, Khosla S, Riggs BL, Spelsberg TC (2003) Phytoestrogen genistein acts as an estrogen agonist on human osteoblastic cells through estrogen receptors α and β. J Cell Biochem 89: 633-646.
39. Riggs BL (1991) Overview of osteoporosis. West J Med 154: 63-77.
40. Setchell KDR, Lydeking-Olsen E (2003) Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. Am J Clin Nutr 78 (3 Suppl): 593S-609S.
41. Soucy NV, Parkinson HD, Sochaski MA, Borghoff SJ (2006) Kinetics of genistein and its conjugated metabolites in pregnant Sprague-Dawley rats following single and repeated genistein administration. Toxicol Sci 90: 230-240.
42. Śliwiński L, Folwarczna J, Janiec W, Grynkiewicz G, Kuzyk K (2005) Differential effects of genistein, estradiol and raloxifene on rat osteoclasts in vitro. Pharmacol Rep 57: 352-359.
43. Taranta A, Brama M, Teti A, De Luca V, Scandurra R, Spera G, Agnusdei D, Termine JD, Migliaccio S (2002) The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30: 368-376.
44. Viereck V, Gründker C, Blaschke S, Siggelkow H, Emons G, Hofbauer LC (2002) Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. J Cell Biochem 84: 725-735.
45. Weaver CM, Cheong JM (2005) Soy isoflavones and bone health: the relationship is still unclear. J Nutr 135: 1243-1237.
46. Williams JP, Jordan SE, Barnes S, Blair HC (1998) Tyrosine kinase inhibitor effects on avian osteoclastic acid transport. Am J Clin Nutr 68 (6 Suppl): 1369S-1374S.
47. Wronski TJ, Yen C-F (1991) The ovariectomized rat as an animal model for postmenopausal bone loss. Cells Materials Suppl 1: 69-74.
48. Yamagishi T, Otsuka E, Hagiwara H (2001) Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis. Endocrinology 142: 3632-3637.